Source[/caption]
At its core, people-pleasing is a survival strategy. It’s not about kindness—it’s about safety. Somewhere along the way, these individuals...
Source[/caption]
Dr Tong Li[/caption]
Dr Tong Li PhD | Cancer Institute NSW Early Career Fellow
Breast Cancer Clinical and Population Health Stream
The Daffodil Centre, Faculty of Medicine and Health, The University of Sydney
Moore Theological College | The University of Sydney | NSW | 2042
MedicalResearch.com: What is the background for this study?
Response: Having a family history of breast cancer is one of the most common risk factors for women. About 8% to 11% of women in the U.S. report having a close relative diagnosed with breast cancer. These women often have dense breasts. Dense breast tissue can make standard digital mammography (DM, also known as 2D mammography) less effective in detecting cancer. Digital breast tomosynthesis (DBT), a 3D imaging technology, has become increasingly used in breast cancer screening because it improves the visibility of lesions and reduces unnecessary callbacks. However, until now, it has been unclear whether DBT offers the same benefits in women with a family history of breast cancer, especially across different family risk levels and breast density types.
Dr. Piper[/caption]
Brian J. Piper, PhD
Department of Medical Education
Center for Pharmacy Innovation & Outcomes
Geisinger College of Health Sciences
Scranton, PA 18509
MedicalResearch.com: What is the background for this study?
Dr. Piper: Tapentadol has an unusual mechanism of action. This opioid is similar to morphine in that it activates mu, the main opiate receptor which is important for pain. This drug also acts similar to an antidepressant like duloxetine (Cymbalta) with equal ability to block both the norepinephrine and the serotonin transporters (Figure 1). The combination of opioid and monoaminergic activity may influence both therapeutic and side effect profiles.
[caption id="attachment_68512" align="aligncenter" width="192"]
Figure 1. Biological mechanism of action of the atypical opioid tapentadol involves binding to the mu opiate receptor, blocking the norepinephrine transporter (NET), and blocking the serotonin transporter (SERT) [1].[/caption]Tapentadol is approved in the US for moderate to severe acute pain, moderate to severe chronic pain, and neuropathic pain associated with diabetic peripheral neuropathy. However, tapentadol is not generally considered first-line for any of these indications. Although this agent has a high potential for abuse and is classified as a Schedule II substance, a manufacturer of extended release tapentadol (Grunenthal) has conducted a misinformation campaign claiming tapentadol has a “minimum potential of abuse”, does not cause respiratory depression (a well-known opioid effect), does not cause any euphoric feelings, has no street value, and is not an opioid [2]. Prior pharmacoepidemiological studies have examined the use patterns of other prescription opioids that can be misused like oxycodone [3], fentanyl [4], meperidine [5] and methadone [6] but there is limited national information about the use of tapentadol.
Photo by Valeria Boltneva[/caption]
When you experience a new or sudden symptom, especially concerning the eyes, it can be quite worrying. The problem is that modern life is very fast-paced, and many people struggle to fit appointments into their day. However, your health is the most important thing of them all, and ignoring symptoms can lead to worsening problems down the road.
If you experience any of the following eye-related symptoms, book an appointment as soon as you can.
Dr. Bertus Eksteen[/caption]
Primary sclerosing cholangitis (PSC) is a liver disease characterized by progressive inflammation and scarring of the bile ducts. PSC still has no known cause or cure and often leads to liver failure or cancer. For patients and clinicians, the lack of answers is deeply frustrating. But that's beginning to change.
Thanks to genetic research, we’re uncovering clues about PSC’s origins—and why it behaves differently from patient to patient. By learning more about the genomic underpinnings of PSC, researchers can create new treatment targets, devise risk profiles for early diagnosis, and even develop better clinical tools for detecting the disease in its earliest stages.
And that path forward doesn’t just start with new treatments — it begins in the lab.
Jingzhen Ginger Yang, PhD, MPH
Principal Investigator at the Center for Injury Research and Policy
Abigail Wexner Research Institute at Nationwide Children’s Hospital
Professor of Pediatrics at The Ohio State University College of Medicine
with a courtesy appointment in the Department of Epidemiolog
in The Ohio State University College of Public Health
MedicalResearch.com: What is the background for this study?
Response: Motor vehicle crashes are the leading cause of death for U.S. teens. Newer vehicles and driver assistance technologies show promise in reducing crashes and injury severities.
Our study found that driving vehicles 6-15 years old had a 19% greater risk of driver death in fatal crashes, and driving vehicles older than 15 years had a 31% greater risk, both compared to driving vehicles 5 years old or newer, regardless of driver age. Additionally, each driver assistance technology already present in vehicles was associated with a 6% reduction in the risk of driver death in fatal crashes.
Dr. Andrei Bakin[/caption]
Andrei Bakin, PhD, Associate Professor of Oncology, Department of Cancer Genetics & Genomics, Roswell Park Comprehensive Cancer Center – first author of “A novel combination immunotherapy for p53 mutant metastatic breast cancer leveraging vulnerabilities in the DNA damage response” and senior author of “Novel triple-drug combination strategy for p53 mutant cancers leveraging their DNA damage response liabilities”
Christos Fountzilas, MD, FACP, Associate Professor of Oncology, Department of Medicine, Roswell Park Comprehensive Cancer Center - and senior author of “A novel combination immunotherapy for p53 mutant metastatic breast cancer leveraging vulnerabilities in the DNA damage response”
Mohammed Alruwaili, MS, PhD, newly graduated doctoral candidate in Cancer Genetics & Genomics at Roswell Park Comprehensive Cancer Center, first author of “Novel triple-drug combination strategy for p53 mutant cancers leveraging their DNA damage response liabilities”
Dr. Gokul Das[/caption]
First author Gokul Das, PhD, Professor of Oncology and Co-Director of the Breast Translational Group, Department of Pharmacology & Therapeutics, Roswell Park Comprehensive Cancer Center
Chetan Oturkar, PhD, Research Assistant Professor in the Department of Pharmacology & Therapeutics, Roswell Park Comprehensive Cancer Center, first author on the study
MedicalResearch.com: What is the background for this study?
Dr. Gokul Das: Triple-negative breast cancer (TNBC) is a very aggressive subtype of breast cancer for which effective targeted therapies are not available, and which rapidly becomes resistant to chemotherapy. TNBC tumors are negative for estrogen receptor α (ERα), progesterone receptor (PR), and HER-2/neu receptor. Endocrine therapy or HER2-targeted therapies are not effective against TNBC. Currently available options including immunotherapy benefit only some patients. They are cost-prohibitive and have severe adverse effects. Therefore, there is an unmet need for rationally designed therapies for TNBC. Although ERα is absent in TNBC, majority of these tumors express estrogen receptor beta (ERβ), a structurally related but functionally distinct isoform of the estrogen receptor coded by a different gene. Tumor suppressor protein p53 is mutated in the majority (80%) of TNBC. p53, when mutated, loses its tumor suppression capabilities, and instead gains oncogenic or tumor-driving functions. One of the major oncogenic functions of mutant p53 is to bind and inactivate another tumor suppressor named p73. The Das laboratory has been focusing on the mechanisms underlying the estrogen receptor β-p53-p73 axis for discovering rational and effective therapeutic strategies against TNBC.
Dr. Siddiqui[/caption]
Mohamed Tausif Siddiqui, MD
The study’s lead author and a Gastroenterology fellow
Cleveland Clinic.
MedicalResearch.com: What is the background for this study?
Response: Our study looked at how the stage of gastric cancer diagnosis has changed over the past two decades in the U.S., using national SEER data. Gastric cancer has long been a challenge because it’s often diagnosed late, when treatment options are limited and survival rates are poor.
But with advancements in endoscopic technology—like high-definition imaging, narrow-band imaging, and endoscopic ultrasound—we wanted to see if these tools were making a difference in catching cancers earlier.
Dr. Robinson[/caption]
Ashley Robinson, MD, lead author
Second-year internal medicine resident
Advocate Lutheran General Hospital
MedicalResearch.com: What is the background for this study?
Response: Briefly, anal cancer makes up around 1% of gastrointestinal cancers and more than 90% of all anal cancers are caused by chronic human papillomavirus or HPV infections.
In previous research, it has been noted that women over the age of 65 have rates that were increasing more than other groups and myself along with my colleagues and the principal investigator of this project, Dr. Eli Ehrenpreis, wanted to further characterize these findings, looking into more specific details of these previously noted trends. Using data from a public database ran by the National Cancer Institute called the Surveillance, Epidemiology and End Results program, also known as SEER, and their statistical analysis software, SEER*Stat, we analyzed anal cancer incidence trends, looking at differences between sex, age, and ethnicity in order to further identify specific groups that have more rapidly increasing rates than others.
Image source: Unsplash[/caption]
Surgeon-scientists represent a critical intersection between clinical practice and scientific innovations. Their unique dual roles allow them to identify pressing clinical challenges and pursue evidence-based solutions through research. However, external pressures in academic medicine have introduced additional obstacles, from institutional shifts in priorities to dwindling time for research.
Dr. Melina Kibbe MD notes how these challenges are compounded by mounting clinical demands, financial pressures, and insufficient support structures, all of which threaten the sustainability of this vital career pathway. Dr. Kibbe is Dean, UVA School of Medicine; Chief Health Affairs Officer, UVA Health; Editor-in-Chief, JAMA Surgery. As academic centers reassess their values, there's growing recognition of the need to better support these professionals.
Dirofilaria repens[/caption]
Introduction
Dirofilaria repens is a filarial nematode responsible for subcutaneous dirofilariasis in domestic and wild canids, felids, and humans. Unlike Dirofilaria immitis, which causes cardiopulmonary disease and is endemic to North America, D. repens tends to reside in subcutaneous tissues, where it forms nodules or migratory swellings. D. immitis is widely studied and routinely screened, while D. repens remains underdiagnosed due to its subtle presentation and emerging zoonotic recognition (Genchi & Kramer, 2017; Capelli et al., 2018).
Dr. Gernhard[/caption]
MedicalResearch.com Interview with:
Dr. Katilyn Gernhard DO
Internal Medicine Resident
Allegheny Health Network Pittsburgh
MedicalResearch.com: What is the background for this study?
Response: The background for this study is the steadily rising prevalence of obesity in the United States, which has been accompanied by an increase in related comorbid conditions, including Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD). Bariatric surgery and GLP-1 receptor agonists are two commonly used treatment options to address obesity and its associated complications.
While both have demonstrated benefits in weight loss and metabolic improvement, there has been limited direct comparison of their effectiveness specifically in patients with MASLD. Our study aimed to address this gap by comparing clinical outcomes in patients with MASLD treated with GLP-1 receptor agonists versus those treated with bariatric surgery.
Dr. Steenson[/caption]
Dr. Simon Steenson PhD
Postdoctoral Research Associate
Department of Nutritional Sciences
King’s College London
MedicalResearch.com: What is the background for this study?
Response: Chronic constipation is something that can be embarrassing, but it affects 1 in 10 people globally. It has a big impact on people’s quality of life and treating constipation has substantial costs for the healthcare system. Dried fruits are recommended for managing constipation, but there are very few studies that have actually tested whether following this advice is helpful. To fill this gap in our knowledge, we completed the largest clinical trial to date to see whether dried fruits and fruit juices could benefit constipation symptoms. 
Dr. Corley[/caption]
Douglas Corley, MD, PhD
Chief Research Officer, The Permanente Medical Group
Kaiser Permanente, Northern California
MedicalResearch.com: What is the background for this study?
Response: Kaiser Permanente Northern California (KPNC) is an integrated health care system that designs and implements population-based programs that support cancer prevention and early detection. In 2006, KPNC began to implement a comprehensive colorectal cancer screening program with the goal of increasing member screening rates, preventing colorectal cancer through polyp removal, and reducing cancer mortality. The initiative identifies whether screening-eligible KPNC members are up to date with their colorectal cancer screening test by either a colonoscopy or by stool-based tests, such as a fecal immunochemical testing (FIT) kit. If they are not up to date with screening, it mails them a FIT kit for at-home testing. Members can also choose other options for colorectal cancer screening, such as a colonoscopy, through their physician.
Pexels image[/caption]
Public health is an expansive field that focuses on improving the well-being of communities and populations. It involves promoting healthy lifestyles, preventing diseases, ensuring access to healthcare, and creating policies that support a healthier society. As global health challenges grow, the demand for skilled public health professionals continues to rise. If you are passionate about making a positive impact on the health of individuals and communities, a career in public health may be a perfect fit. This article explores various career paths in public health, including opportunities for education and the roles you can pursue in this dynamic and essential field.
Dr. Cuomo[/caption]
Raphael E. Cuomo, PhD, MPH, CPH, FRSPH
Professor, School of Medicine
University of California, San Diego
MedicalResearch.com: What is the background for this study?
Response: Colon cancer remains a leading cause of cancer-related death worldwide. Recent years have seen a substantial increase in cannabis use, but limited research has explored its potential influence on cancer outcomes. We conducted a large-scale retrospective cohort study using real-world clinical data to investigate whether a diagnosis of cannabis use disorder prior to colon cancer diagnosis was associated with survival outcomes.
Finishing drug treatment is an exciting accomplishment, but your work in recovery is never done! It’s time to live your life on its terms and meet the challenges you face. After all, one of the reasons you went away from home was to get away from everyday stress and triggers. When you get home, you’ll need to manage those while staying sober. Managing your recovery requires commitment, flexibility, and willingness. You’ll need to rely on the tools you’ve learned during treatment to solidify new behaviors.
Here are some ways to stay on track and continue your journey when you’re home.
Dr. Shreenivas[/caption]
MedicalResearch.com Interview with:
Aditya Shreenivas M.D., M.S.
Assistant Professor
Department of Medical Oncology & Therapeutics Research
City of Hope
MedicalResearch.com: What is the background for this study?
Response: Nasopharyngeal carcinoma (NPC) is a highly aggressive tumor of the head and neck region with a distinct geographical distribution, with incidence rates as high as 30 per 100,000 in endemic regions like Asia and North Africa but less than 1 per 100,000 worldwide. Despite comprehensive curative intent therapy, up to 30% of patients with advanced NPC experience treatment failure, primarily due to recurrence and/or metastasis. This high mortality rate highlighted the urgent need for effective treatments.
Clinical trials (JUPITER-02, CAPTAIN-1st, and RATIONALE-309) showed improved progression-free survival by adding anti-PD-1 antibodies to chemotherapy for first-line treatment of recurrent or metastatic NPC. However, these studies were conducted exclusively in Asian populations.
Penpulimab is a humanized anti-PD-1 antibody that's unique because it is a IgG1 subtype with a modified Fc segment. This structure potentially improves efficacy and safety compared to other anti-PD-1 drugs through lower immune-related adverse events.
Prof. Hermona Soreq[/caption]
Prof. Hermona Soreq
Professor of Molecular Neuroscience
The Edmond and Lily Safra Center for Brain Sciences
Department of Biological Chemistry
The Alexander Silberman Institute of Life Sciences
The Hebrew University of Jerusalem
The Edmond J. Safra Campus, Givat Ram Jerusalem Israel and
[caption id="attachment_68187" align="alignleft" width="125"]
Shani Vaknine[/caption]
Shani Vaknine, Ph.D. candidate
Brain and Behavioral Sciences
The Hebrew University
MedicalResearch.com: What is the background for this study?
Response: We’ve long known that maternal stress during pregnancy can affect her baby’s development, but the molecular mechanisms behind this remained unclear. In our study, we explored how psychosocial stress experienced by the mother in late pregnancy influences tiny molecular fragments in the newborn’s blood. These fragments, called transfer RNA fragments or tRFs, were considered for many years to be disposable, but have recently been shown to have important biological functions.
Dr. Jowell[/caption]
Ashley Jowell, MD,
Internal Medicine Resident Physician
Duke University
[caption id="attachment_68139" align="alignleft" width="125"]
Dr. Moyland[/caption]
Cynthia Moylan, MD
Associate Professor of Medicine,
Division of Gastroenterology
Duke University Health System
MedicalResearch.com: What is the background for this study?
Response: Metabolic dysfunction can lead to several health problems including metabolic dysfunction associated steatotic liver disease (MASLD), is driven by different factors, including: a person’s behavioral or lifestyle factors, environmental factors, and genetics. Limited research exists regarding genetic , epigenetic, or other factors that might impact development of metabolic dysfunction and MASLD. Our group has previously shown that alterations in DNA methylation (a type of epigenetic change), identifiable both in liver tissue and in blood, associate with MASLD and its progression to more severe liver disease. Whether DNA methylation that impacts imprinted gene expression also associates with metabolic dysfunction and MASLD risk remains largely unknown.
In this project, we explored imprinted genes: imprinting is a normal process that regulates genes by silencing one parental copy (either the maternal or the paternal) so that only one copy is expressed. Imprinting is an important biological process for development and has a disproportionate impact on disease - in fact, imprinted genes are hypothesized to affect 1-6% of the human genome. We sought to explore how altered DNA methylation of imprint control regions (ICRs) that help ‘control’ these imprinted genes might impact development of metabolic dysfunction in children (and hence potentially even in adults).
Dr. Ribeiro[/caption]
MedicalResearch.com Interview with:
Ulysses Ribeiro M.D., PhD
Associate Professor of Digestive Surgery
Instituto do Câncer do Estado de São Paulo
MedicalResearch.com: What is the background for this study?
Response: Gastric cancer (GC) is one of the most common malignancies worldwide, and the 3th leading cause of cancer-related death. Although the diagnosis and treatment have substantially improved in recent years, the five-year survival rate of gastric cancer is still low due to local recurrence and distant metastasis.
Gastric cancer is a complex and heterogeneous disease that involves a series of genetic, epigenetic and phenotypic changes. Still, differences in prognosis and response to chemotherapy or immunotherapy are frequently seen in tumors with the same histological type and stage due to various genetic mutations and abnormal signaling pathways underlying the progression of this disease.
Thus, the purpose of this study was to perform a whole-gene sequencing to identify variants in genes with prognostic value in patients with gastric cancer who underwent curative surgery.
Luke Cavanah B.S.[/caption]
Luke Cavanah, BS
Department of Medical Education
Geisinger College of Health Sciences
Scranton, PA, 18509
MedicalResearch.com: What is the background for this study?
Response: Almost a third of patients with medication-treated major depressive disorder will fail at least two depressants—many patients failing more.1 Esketamine is an intranasal medication that was FDA-approved in 2019 for such patients when used in conjunction with an oral antidepressant.2 Esketamine also is unique from the more traditional oral antidepressants in its mechanism of action, quick onset, and evidence for treatment of acute suicidality.3 While esketamine has been of much interest for these last few years, a recent study found low and geographically variable use of this medication within the Medicaid population.4 We were interested in investigating esketamine treatment utilization among Medicare patients in 2019 and 2020.
Source[/caption]
With weight loss medications taking center stage in health discussions, Ozempic has become a household name. While originally developed to treat and control type 2 diabetes, it has gained global attention for its potential role in weight loss. For individuals exploring new avenues to support their health goals, getting Ozempic border free emerges as a convenient way to access the medication.
In this article, we'll break down how Ozempic works, its effectiveness for weight loss, possible side effects, and what you should consider before starting it. Whether you're dealing with weight-related health issues or simply exploring safe, medical fat loss aids, this guide will help clarify your options.
A broken tailbone may not sound very serious at first. But if you have ever hurt your tailbone, you know how painful and difficult it can be. Even sitting down or standing up can become a big problem. If your injury was caused by someone else’s carelessness, you might be wondering if you can file a lawsuit. The good news is that you can, but there are a few important things you should know first.
Before filing a case, it is important to understand the symptoms of a broken tailbone. Some of the common symptoms include sharp discomfort in the bottom part of your spine, discomfort while standing or sitting for extended periods, bruises, swelling, and numbness. In case you have these symptoms following a fall, automobile accident, or some other injury, see a physician immediately. Proper diagnosis is the first step before thinking about a legal case.
Let’s talk about when you can file a lawsuit and what you should keep in mind.
Image source[/caption]
Magnesium is one of the most essential minerals that our bodies need for optimal functioning. It plays a pivotal role in over 300 biochemical reactions, including energy production, muscle function, and nervous system regulation. However, despite its importance, magnesium deficiency is quite common, with many people not getting enough of it from their diet alone. To combat this, various magnesium supplements have flooded the market, and one of the most advanced options is Glycinate 3-in-1. Developed by leading brands like Vinco Supplements, this formula promises superior absorption, offering a solution to the age-old problem of low magnesium intake. In this article, we’ll explore what Glycinate 3-in-1 is, how it works, and why it's becoming a game-changer in magnesium supplementation.
Dr. Layton[/caption]
Anita T. Layton PhD
Canada 150 Research Chair in Mathematical Biology and Medicine
Professor of Applied Mathematics, Computer Science, Pharmacy and Biology
University of Waterloo
MedicalResearch.com: What is the background for this study? Why did you decide to examine a potential link between potassium intake and lowering blood pressure?
Response: Our diet is so very different from our long-ago ancestors, especially in terms of sodium-to-potassium ratio. We eat so much sodium and so little potassium, that ratio is reversed in our ancestors as well as people in isolated tribes, where high blood pressure is very rare. So, let's figure out why and thus this stud
MedicalResearch.com: In layman's terms, how the ratio of potassium to sodium can both negatively and positively impact the body?
Response: Having more potassium in your body would encourage the kidneys to pee out more sodium (and water), which lowers blood pressure.